Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracavitary IL-2 and LAK Cell Therapy for Malignant Gliomas
NCT00003067Phase 2Suspended
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 1997
- Modality
- Cytokines & Interferons, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of lymphokine-activated killer cells, aldesleukin in malignant glioma, sponsored by Weill Cornell Medicine. Started Jul 1997; status: suspended.
02
Drugs
lymphokine-activated killer cellsaldesleukin
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00003067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003067.